Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40

Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $39 to $40.